Akoya Biosciences, Inc. (AKYA) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	8-K	10-K	10-K	S-1/A
Revenues:
North America		28.0	20.2	22.2
APAC		12.5	10.4	9.4
EMEA		14.4	11.9	10.6
Total revenues [+]	74.9	54.9	42.4	42.2
Products	57.7			36.3
Services	17.2			5.9
Revenue growth [+]	36.3%	29.4%	0.5%
North America		38.9%	-9.1%
APAC		20.4%	10.2%
EMEA		21.1%	12.0%
Cost of goods sold	31.5	20.7	16.5	17.6
Gross profit	43.4	34.2	25.9	24.7
Gross margin	58.0%	62.3%	61.0%	58.4%
Selling, general and administrative	79.7	51.0	24.0	26.4
Research and development	23.2	15.7	9.6	8.8
Other operating expenses	6.6	2.1	0.5
EBITDA [+]		-34.5	-8.2	-10.4
EBITDA growth	91.6%	321.0%	-21.6%
EBITDA margin	-88.3%	-62.8%	-19.3%	-24.7%
Depreciation and amortization		4.8	3.8	3.1
EBIT [+]	-66.1	-39.3	-12.0	-13.5
EBIT growth	68.2%	227.2%	-11.1%
EBIT margin	-88.3%	-71.6%	-28.3%	-32.0%
Non-recurring items [+]				-1.2
Unusual expense				-1.2
Interest expense	4.6	3.1	2.7	1.9
Interest expense	4.6	3.1	2.7	1.9
Other income (expense), net [+]	0.1	-0.7	-1.9	-0.4
Gain (loss) on debt retirement		2.5	-1.7
Change in fair value of warrants		-2.7	-0.3
Change in value of contingent liability		2.1	0.5
Other		-0.4	0.0
Pre-tax income	-70.5	-43.1	-16.7	-14.6
Income taxes	0.1	-0.1	0.0	-0.2
Tax rate		0.3%		1.3%
Net income	-70.6	-44.4	-21.8	0.0
Net margin	-94.4%	-80.8%	-51.3%	0.0%

Basic EPS [+]	($1.87)	($1.65)	($9.18)	$0.00
Growth	13.4%	-82.0%
Diluted EPS [+]	($1.87)	($1.65)	($9.18)	$0.00
Growth	13.4%	-82.0%

Shares outstanding (basic) [+]	37.7	26.9	2.4	2,276.0
Growth	40.3%	1034.6%	-99.9%
Shares outstanding (diluted) [+]	37.7	26.9	2.4	2,276.0
Growth	40.3%	1034.6%	-99.9%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.